News | May 22, 2023
Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
India’s efforts are aimed at boosting health at the last mile
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
These initiatives aim to improve access to healthcare for rare disease patients
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
